| 저자(한글) |
the INTENS Study Group,Vriens, B.E.P.J.,de Vries, B.,Lobbes, M.B.I.,van Gastel, S.M.,van den Berkmortel, F.W.P.J.,Smilde, T.J.,van Warmerdam, L.J.C.,de Boer, M.,van Spronsen, D.J.,Smidt, M.L.,Peer, P. |
| 초록 |
Background: The aim of this study was to evaluate the accuracy of clinical imaging of the primary breast tumour post-neoadjuvant chemotherapy (NAC) related to the post-neoadjuvant histological tumour size (gold standard) and whether this varies with breast cancer subtype. In this study, results of both magnetic resonance imaging (MRI) and ultrasound (US) were reported. Methods: Patients with invasive breast cancer were enrolled in the INTENS study between 2006 and 2009. We included 182 patients, of whom data were available for post-NAC MRI (n=155), US (n=123), and histopathological tumour size. Results: MRI estimated residual tumour size with 25 =2 26, P 75 =1 100) and 49% (P 25 =2 22, P 75 =1 100) for MRI and US, respectively (P=0.06). Conclusions: In this study, US was at least as good as breast MRI in providing information on residual tumour size post-neoadjuvant chemotherapy. However, both modalities suffered from a substantial percentage of over- and underestimation of tumour size and in addition both showed a low negative predictive value of pathologic complete remission (Gov nr: NCT00314977). |
